Tumoral Vitamin D Synthesis by CYP27B1 1-α-Hydroxylase Delays Mammary Tumor Progression in the PyMT-MMTV Mouse Model and Its Action Involves NF-κB Modulation.

Biologically active vitamin D (1,25-dihydroxycholecalciferol or 1,25(OH)2D) is synthetized from inactive prohormone 25-hydroxycholecalciferol (25(OH)D) by the enzyme CYP27B1 1-α-hydroxylase in kidney and several extrarenal tissues including breast. Although the development of breast cancer has been linked to inadequate vitamin D status, the importance of bioactive vitamin D production within tumors themselves is not fully understood. To investigate the role of tumoral vitamin D production in mammary epithelial cell progression to breast cancer, we conducted a Cre-loxP-mediated Cyp27b1 gene ablation in the mammary epithelium of the polyoma middle T antigen-mouse mammary tumor virus (PyMT-MMTV) mouse breast cancer model. Targeted ablation of Cyp27b1 was accompanied by significant acceleration in initiation of spontaneous mammary tumorigenesis. In vivo, cell proliferation, angiogenesis, cell cycle progression, and survival markers were up-regulated in tumors by Cyp27b1 ablation, and apoptosis was decreased. AK thymoma (AKT) phosphorylation and expression of several components of nuclear factor κB (NF-κB), integrin, and signal transducer and activator of transcription 3 (STAT3) signaling pathways were increased in Cyp27b1-ablated tumors compared with nonablated controls. In vitro, 1,25(OH)2D treatment induced a strong antiproliferative action on tumor cells from both ablated and nonablated mice, accompanied by rapid disappearance of NF-κB p65 from the nucleus and segregation in the cytoplasm. In contrast, treatment with the metabolic precursor 25(OH)D was only effective against cells from nonablated mice. 25(OH)D did not inhibit growth of Cyp27b1-ablated cells, and their nuclear NF-κB p65 remained abundant. Our findings demonstrate that in-tumor CYP27B1 1-α-hydroxylase activity plays a crucial role in controlling early oncogene-mediated mammary carcinogenesis events, at least in part by modulating tumoral cell NF-κB p65 nuclear translocation.

[1]  W. Muller,et al.  Chemoprevention Activity of 25-Hydroxyvitamin D in the MMTV-PyMT Mouse Model of Breast Cancer , 2014, Cancer Prevention Research.

[2]  A. Lykkesfeldt,et al.  1α,25-Dihydroxyvitamin D3 inhibits cell growth and NFκB signaling in tamoxifen-resistant breast cancer cells , 2014, Steroids.

[3]  Jing-quan Li,et al.  Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis. , 2014, The Journal of clinical endocrinology and metabolism.

[4]  I. Reid,et al.  The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. , 2014, The lancet. Diabetes & endocrinology.

[5]  Jie Du,et al.  Vitamin D Receptor Inhibits Nuclear Factor κB Activation by Interacting with IκB Kinase β Protein* , 2013, The Journal of Biological Chemistry.

[6]  L. Verlinden,et al.  Antineoplastic effects of 1,25(OH)2D3 and its analogs in breast, prostate and colorectal cancer. , 2013, Endocrine-related cancer.

[7]  Abena B. Redwood,et al.  BRCA1 loss activates cathepsin L–mediated degradation of 53BP1 in breast cancer cells , 2013, The Journal of cell biology.

[8]  John H. White,et al.  Vitamin D receptor as a master regulator of the c-MYC/MXD1 network , 2012, Proceedings of the National Academy of Sciences.

[9]  W. Muller,et al.  PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target. , 2011, The Journal of clinical investigation.

[10]  S. Ghosh,et al.  Crosstalk in NF-κB signaling pathways , 2011, Nature Immunology.

[11]  A. Brożyna,et al.  Expression of vitamin D receptor decreases during progression of pigmented skin lesions. , 2011, Human pathology.

[12]  Peizhan Chen,et al.  Meta-analysis of vitamin D, calcium and the prevention of breast cancer , 2010, Breast Cancer Research and Treatment.

[13]  M. Karin,et al.  Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. , 2010, Cytokine & growth factor reviews.

[14]  Shanling Xu,et al.  The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapy , 2010, Expert opinion on therapeutic targets.

[15]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[16]  M. Friedrich,et al.  25-Hydroxyvitamin D3 1alpha-hydroxylase splice variants in benign and malignant ovarian cell lines and tissue. , 2009, Anticancer research.

[17]  E. Bertone-Johnson Vitamin D and breast cancer. , 2009, Annals of epidemiology.

[18]  N. Weigel,et al.  1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. , 2009, Endocrinology.

[19]  E. Sarchielli,et al.  The vitamin D receptor agonist elocalcitol inhibits IL‐8‐dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF‐kB pathways , 2009, The Prostate.

[20]  D. Deb,et al.  1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-{kappa}B pathway. , 2009, American journal of physiology. Renal physiology.

[21]  C. Ulrich,et al.  Vitamin D insufficiency in a multiethnic cohort of breast cancer survivors. , 2008, The American journal of clinical nutrition.

[22]  D. Trump,et al.  Vitamin D signalling pathways in cancer: potential for anticancer therapeutics , 2007, Nature Reviews Cancer.

[23]  J. Reichrath,et al.  25-Hydroxyvitamin D3 1alpha-hydroxylase splice variants in breast cell lines MCF-7 and MCF-10. , 2007, Cancer genomics & proteomics.

[24]  R. Recker,et al.  Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. , 2007, The American journal of clinical nutrition.

[25]  Zhiyuan Hu,et al.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.

[26]  Y. Suárez,et al.  Vitamin D regulates the phenotype of human breast cancer cells. , 2007, Differentiation; research in biological diversity.

[27]  D. Notterman,et al.  Gene expression profiling changes induced by a novel Gemini Vitamin D derivative during the progression of breast cancer. , 2006, Biochemical pharmacology.

[28]  M. Campbell,et al.  Vitamin D status and breast cancer risk. , 2006, Anticancer research.

[29]  E. Kallay,et al.  Nutrients regulate the colonic vitamin D system in mice: relevance for human colon malignancy. , 2006, The Journal of nutrition.

[30]  R. Benya,et al.  Expression of Vitamin D Receptor and 25-Hydroxyvitamin D3-1α-Hydroxylase in Normal and Malignant Human Colon , 2005, Cancer Epidemiology Biomarkers & Prevention.

[31]  J. Welsh,et al.  Vitamin D receptor (VDR) ablation alters carcinogen-induced tumorigenesis in mammary gland, epidermis and lymphoid tissues , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[32]  M. Guy,et al.  Autocrine Metabolism of Vitamin D in Normal and Malignant Breast Tissue , 2005, Clinical Cancer Research.

[33]  M. Holick Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. , 2004, The American journal of clinical nutrition.

[34]  J. Welsh,et al.  Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice. , 2004, Carcinogenesis.

[35]  M. Willingham,et al.  Pancreatic cancer cells express 25-hydroxyvitamin D-1α-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3 , 2004 .

[36]  I. Ellis,et al.  Expression of luminal and basal cytokeratins in human breast carcinoma , 2004, The Journal of pathology.

[37]  Jeffrey B. Cheng,et al.  Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[38]  P. Tuohimaa,et al.  25‐Hydroxyvitamin D3 is an active hormone in human primary prostatic stromal cells , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  Jeffrey W Pollard,et al.  Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. , 2003, The American journal of pathology.

[40]  M. Holick Vitamin D: A millenium perspective , 2003, Journal of cellular biochemistry.

[41]  J. Rhim,et al.  Targeted Disruption of the 25-Hydroxyvitamin D3 1α-Hydroxylase Gene in ras-Transformed Keratinocytes Demonstrates That Locally Produced 1α,25-Dihydroxyvitamin D3 Suppresses Growth and Induces Differentiation in an Autocrine Fashion11 Canadian Institutes of Health Research Grant MT10839 (to R.K.). , 2002 .

[42]  R. Glazer,et al.  Delayed mammary gland involution in MMTV-AKT1 transgenic mice , 2002, Oncogene.

[43]  L. Hennighausen,et al.  Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice , 2001, Transgenic Research.

[44]  R. Kremer,et al.  Calcitroic Acid Is a Major Catabolic Metabolite in the Metabolism of 1α-Dihydroxyvitamin D2 , 2001 .

[45]  J. Welsh,et al.  Functions of 1α,25-dihydroxyvitamin D3 in mammary gland: from normal development to breast cancer , 2001, Steroids.

[46]  M. Hakama,et al.  Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland) , 2000, Cancer Causes & Control.

[47]  N. Bundred,et al.  1α,25-Dihydroxyvitamin D3 Inhibits Angiogenesis In Vitro and In Vivo , 2000 .

[48]  W. Kuo,et al.  Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene , 2000, Nature Genetics.

[49]  M. Rudnicki,et al.  Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[50]  V. Soldatenkov,et al.  Novel 19-nor-hexafluoride vitamin D3 analog (Ro 25-6760) inhibits human colon cancer in vitro via apoptosis. , 1999, International journal of oncology.

[51]  C. Glass,et al.  Coactivator and corepressor complexes in nuclear receptor function. , 1999, Current opinion in genetics & development.

[52]  H. Matsumoto,et al.  Antitumor effect of 22-oxacalcitriol on estrogen receptor-negative MDA-MB-231 tumors in athymic mice. , 1999, Oncology reports.

[53]  A. Mackay,et al.  Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[54]  R. Evans,et al.  The RXR heterodimers and orphan receptors , 1995, Cell.

[55]  N. Brünner,et al.  1α,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cellsin vitro , 1994, Clinical & Experimental Metastasis.

[56]  G. Schwartz,et al.  Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation , 1992, Cancer.

[57]  J. Rhim,et al.  Relative resistance to 1,25-dihydroxyvitamin D3 in a keratinocyte model of tumor progression. , 1992, The Journal of biological chemistry.

[58]  T. Pepersack,et al.  Calcium and vitamin D metabolism in granulomatous diseases , 1992, Clinical Rheumatology.

[59]  R. Cardiff,et al.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.

[60]  J. F. Young,et al.  Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. , 1990, Preventive medicine.

[61]  C. Garland,et al.  SERUM 25-HYDROXYVITAMIN D AND COLON CANCER: EIGHT-YEAR PROSPECTIVE STUDY , 1989, The Lancet.

[62]  D. Deb,et al.  1 , 25-Dihydroxyvitamin D 3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-B pathway , 2009 .

[63]  N. Weigel,et al.  1,25(OH)2D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. , 2009 .

[64]  A. Douvdevani,et al.  Vitamin D decreases NFkappaB activity by increasing IkappaBalpha levels. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[65]  A. Mercurio,et al.  Mobilization and activation of a signaling competent alpha6beta4integrin underlies its contribution to carcinoma progression. , 2005, Cancer metastasis reviews.

[66]  J. Welsh,et al.  Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells , 2004, Breast Cancer Research and Treatment.

[67]  M. Brentani,et al.  Antiproliferative effects of 1,25-dihydroxyvitamin D3 on breast cells: a mini review. , 2002, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[68]  F. Glorieux,et al.  Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. , 2001, Endocrinology.

[69]  N. Bundred,et al.  1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. , 2000, Circulation research.

[70]  J. Keski‐Oja,et al.  1 a , 25-Dihydroxyvitamin D 3 and Its Analogues DownRegulate Cell Invasion-associated Proteases in Cultured Malignant Cells 1 , 2000 .

[71]  M. Haussler,et al.  The vitamin D hormone and its nuclear receptor: molecular actions and disease states. , 1997, The Journal of endocrinology.

[72]  N. Brünner,et al.  1 alpha,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. , 1994, Clinical & experimental metastasis.

[73]  B. Roos,et al.  Concurrent measurement of plasma levels of vitamin D3 and five of its metabolites in normal humans, chronic renal failure patients, and anephric subjects. , 1981, The Journal of laboratory and clinical medicine.